A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World

Enrolling by invitationOBSERVATIONAL

Enrollment

285,327

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

December 19, 2025

Study Completion Date

December 19, 2025

Conditions

OverweightObesityHeart Failure (HF)Atherosclerotic Cardiovascular Disease (ASCVD)Primary Prevention

Interventions

OTHER

No treatment given

OTHER

No treatment given

Trial Locations (1)

Novo Nordisk Investigational, Plainsboro